Vascepa is a prescription medication that contains the active ingredient icosapent ethyl, which is used to treat high levels of triglycerides in the blood. According to the sources provided, there are some exclusions for Vascepa coverage.

The first source, Drug Patent Watch [1], provides information on the patents for Vascepa. This source does not provide information on exclusions for Vascepa coverage.

The second source, Cigna [2], provides a coverage position criteria for omega-3 fatty acid products, including Vascepa. According to this criteria, Vascepa is covered when prescribed for patients with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL) who have not responded to diet and exercise. However, there are some exclusions to coverage, including use in patients with known hypersensitivity to icosapent ethyl or any component of the formulation, and use in patients with hepatic impairment.

The third source, Aetna [3], provides a search tool for finding medications, including Vascepa. According to this source, Vascepa is covered for the treatment of severe hypertriglyceridemia in patients who have not responded to diet and exercise. However, there are some exclusions to coverage, including use in patients with known hypersensitivity to icosapent ethyl or any component of the formulation, and use in patients with hepatic impairment.

In conclusion, based on the sources provided, there are some exclusions for Vascepa coverage. Patients with known hypersensitivity to icosapent ethyl or any component of the formulation, and patients with hepatic impairment are excluded from coverage. Vascepa is covered for the treatment of severe hypertriglyceridemia in patients who have not responded to diet and exercise.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0051_coveragepositioncriteria_omega3-fatty_acid_products.pdf
[3] https://www.aetna.com/individuals-families/find-a-medication.html